Merck completed an exclusive global licensing and collaboration deal with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor described as a precision cancer candidate designed to target mutant KRAS in active signaling state. Financial terms include $400 million up front and potential consideration of up to $2.13 billion tied to development, commercialization, and milestone achievements across multiple indications. SciBrunch has positioned SPR2015 based on preclinical activity across KRAS G12D-mutant tumor models. Merck’s move adds a new modality focus around small-molecule precision oncology, complementing ongoing efforts in targeted protein degradation and next-generation cancer combinations. For SciBrunch, the partnership provides a funding and development pathway toward first-in-human studies anticipated toward the end of 2026, contingent on program progress.